$16.14
-0.27-1.65%
Last update: Nov 11, 8:07 AM
Ultragenyx Pharmaceutical Inc
RARENASDAQ
Ultragenyx Pharmaceutical fell 50.6% from $33.25 to $16.41, behind the S&P 500's +9.8%. Its worst day was Sep 3 (−44.0%), and its low came Sep 16 at $12.88.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Ultragenyx Pharmaceutical closed at its highest level of the year, 9.9% above where the year started.
+0.2% · S&P 500 +0.1%
Ultragenyx Pharmaceutical shares fell 42.3%, while the S&P 500 fell 0.4%.
Story events cover the past 12 months · Times ET
−42.3% · S&P 500 −0.4%
EPS of $-1.29 missed the $-1.18 estimate on $207.0M revenue (est. $202.3M); FY revenue guidance of $730.0M–$760.0M against the $785.4M consensus.
−12.7% · S&P 500 +0.1%
EPS of $-1.84 missed the $-1.48 estimate on $136.0M revenue (est. $159.0M); FY revenue guidance of $730.0M–$760.0M against the $747.1M consensus.
+3.7% · S&P 500 +1.4%
EPS of $-0.90 beat the $-1.16 estimate on $214.0M revenue (est. $182.5M); FY revenue guidance of $730.0M–$760.0M against the $742.5M consensus.
−3.4% · S&P 500 −0.2%
Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI)NOVATO, Calif., Sept.
−44.0%, the year's worst day, on 27M shares, the year's heaviest volume · S&P 500 +1.0%
Ultragenyx Pharmaceutical closed at its lowest level of the year, 61.3% below where the year started.
−1.5% · S&P 500 −0.4%
EPS of $-1.16 missed the $-0.83 estimate on $173.0M revenue (est. $183.8M); FY revenue guidance of $730.0M–$760.0M against the $758.7M consensus.
+3.2% · S&P 500 +1.7%
Where it ended: a close of $16.41 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $0.42, revenue est. $232.5M).
Nothing in the past 12 months.
All RARE dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RARE and SPY from Benzinga historical bars. Not investment advice.
